Brad Baltz

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Researcher

UA Fort Smith primary UAMS

Also affiliated: Merck & Co., Inc., Rahway, NJ, USA (United States) (2019); City Of Hope National Medical Center (2007); Cleveland Clinic (2007); Mercy Medical Center (2007); University of Tennessee Health Science Center (2014); Juravinski Cancer Centre (2007); Arkansas Cardiology (2011–2013); City of Hope (2007); CHI St. Vincent (2021–2022); Hematology Oncology Associates (2007); Hematology Oncology Consultants (2007); Covance (United States) (2022)

Faculty Researcher

5 h-index 9 pubs 89 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

Brad Baltz's research has focused on medical case studies, particularly in the context of neurological disorders and their treatment. His work includes investigating potential adverse effects of immunosuppressive agents used for multiple sclerosis, such as Fingolimod. One publication examines the co-occurrence of primary mediastinal large B-cell lymphoma in a patient receiving Fingolimod for relapsing-remitting multiple sclerosis. Another publication details a case of Pembrolizumab-induced myocarditis and delayed acute inflammatory demyelinating polyradiculoneuropathy. Baltz's scholarship metrics include an h-index of 5, with 9 total publications and 89 total citations. He has collaborated with researchers from the University of Arkansas for Medical Sciences, including Joseph G. Chacko and Paul W. Stout.

Metrics

h-index: 5
Publications: 9
Citations: 89

Selected Publications

Pembrolizumab-Induced Myocarditis and Delayed Acute Inflammatory Demyelinating Polyradiculoneuropathy (2022)

Cureus 4 citations DOI OpenAlex
Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis (2021)

Multiple Sclerosis and Related Disorders 7 citations DOI OpenAlex